Exelixis (EXEL) Free Cash Flow (2010 - 2026)
Exelixis (EXEL) posted quarterly Free Cash Flow of $250.3 million for Q2 2026, up 20.07% year-over-year from $208.5 million in Q2 2025, and down 24.68% quarter-over-quarter from $332.4 million in Q1 2026.
Analysis
Exelixis (EXEL) Free Cash Flow (2010 - 2026) Analysis & Trends
Exelixis' Free Cash Flow history runs 17 years deep, the most recent figure standing at $250.3 million for Q2 2026.
- In Q2 2026, Free Cash Flow rose 20.07% year-over-year to $250.3 million; the TTM figure through Apr 2026 stood at $917.7 million (up 11.79% YoY), while the FY2026 annual figure was $875.8 million, up 30.42% from the prior year.
- Free Cash Flow for Q2 2026 stood at $250.3 million, down from $332.4 million in the prior quarter.
- The five-year high for Free Cash Flow was $332.4 million in Q1 2026, with the low at -$2.6 million in Q4 2023.
- The 5-year median for Free Cash Flow is $113.0 million (2024), against an average of $142.7 million.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow tumbled 104.01% in 2023, then soared 9315.52% in 2025.
- Exelixis' Free Cash Flow stood at $64.0 million in 2022, then sank by 104.01% to -$2.6 million in 2023, then jumped by 10362.91% to $263.1 million in 2024, then advanced by 9.77% to $288.8 million in 2025, then retreated by 13.33% to $250.3 million in 2026.
- Business Quant data shows EXEL's Free Cash Flow at $250.3 million in Q2 2026, $332.4 million in Q1 2026, and $288.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 300.93 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 300.93 Mn |
| Apr 3, 2026 | 250.34 Mn |
| Jan 2, 2026 | 332.36 Mn |
| Oct 3, 2025 | 288.84 Mn |
| Jul 4, 2025 | 46.16 Mn |
| Apr 4, 2025 | 208.49 Mn |
| Jan 3, 2025 | 236.29 Mn |
| Sep 27, 2024 | 263.14 Mn |
| Jun 28, 2024 | 112.98 Mn |
| Mar 29, 2024 | 59.13 Mn |
| Dec 29, 2023 | -2.56 Mn |
| Sep 29, 2023 | 107.99 Mn |
| Jun 30, 2023 | 115.04 Mn |
| Mar 31, 2023 | 72.38 Mn |
| Dec 30, 2022 | 63.98 Mn |
| Sep 30, 2022 | 105.03 Mn |
| Jul 1, 2022 | 23.79 Mn |
| Apr 1, 2022 | 142.11 Mn |
| Dec 31, 2021 | 90.49 Mn |
| Oct 1, 2021 | 68.81 Mn |